Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia

Vilas Navapurkar FFICM *1 , Josefin Bartholdson Scott PhD*2, Mailis Maes MPhil², Ellen Higginson PhD², Sally Forrest BSc², Joana Pereira-Dias MSc², Surendra Parmar MSc³, Emma Heasman-Hunt BSc³, Petra Polgarova MSc¹, Jo Brown MClinRes¹, Lissamma Titti BN¹, William PW Smith BA⁴, Matthew Routledge MB BS⁵, David Sapsford MFRPSII⁶, M.Estée Török PhD $^{7.8}$, David A Enoch FRCPath³, Vanessa Wong PhD³, Martin D Curran PhD³, Nicholas M Brown MD³, Jurgen Herre PhD 9 , Gordon Dougan FRS², Andrew Conway Morris PhD $^{1.10**}$

- 1. John V Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
- 2. Cambridge Institute of Therapeutic Immunology & Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
- 3. Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- 4. Clinical School, University of Cambridge, Cambridge, United Kingdom
- 5. Infectious Diseases, Addenbrooke's Hospital, Cambridge, United Kingdom
- 6. Pharmacy Department, Addenbrooke's Hospital, Cambridge, United Kingdom
- 7. Department of Medicine, University of Cambridge
- 8. Department of Microbiology, Cambridge University Hospitals NHS Foundation Trust, United Kingdom
- 9. Respiratory Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom
- 10. Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, United Kingdom

**Address for correspondence Andrew Conway Morris Division of Anaesthesia Department of Medicine Level 4, Addenbrooke's Hospital Hills Road Cambridge CB2 0QQ Email: mozza@doctors.org.uk

Email: mozza@doctors.org.u Phone: +44 (0)1223 217889

Running title: Rapid syndromic diagnostic for severe pneumonia

Word count: 3555

^{*}The identified authors contributed equally to the manuscript.

Abstract

Rationale

The diagnosis of infectious diseases has been hampered by reliance on microbial culture. Cultures take several days to return a result and organisms frequently fail to grow. In critically ill patients this leads to the use of empiric, broad-spectrum antimicrobials and compromises effective stewardship. The objective of this study was to establish the performance and clinical utility of a syndromic diagnostic approach to severe pneumonia.

Methods

Single ICU observational cohort study with contemporaneous comparator group. We developed and implemented a TaqMan array card (TAC) covering 52 respiratory pathogens in ventilated patients with suspected pneumonia. The time to result was compared against conventional culture, and sensitivity compared to conventional microbiology and metagenomic sequencing. We observed the clinician decisions in response to array results, comparing antibiotic free days (AFD) between the study cohort and comparator group.

Results

95 patients were enrolled with 71 forming the comparator group. TAC returned results 61 hours (IQR 42-90) faster than culture. The test had an overall sensitivity of 99% (95% CI 98-99%) compared to conventional culture and metagenomic sequencing. In 53% of patients the TAC results altered clinical management, with 64% of changes leading to de-escalation, 27% to an increase in spectrum, and investigations for alternative diagnoses in 9%. There was a significant difference in the distribution of AFDs with more AFDs in the TAC group (p=0.02).

Conclusions

Implementation of a customised syndromic diagnostic approach to pneumonia led to faster results, with high sensitivity and measurable impact on clinical decision making.

Abstract word count:246

Keywords: Critical Care, Pneumonia, Molecular pathology, Antimicrobial stewardship

Trial registration NCT03996330 -registered 24/6/2019

Authorship (CReDIT)

VN -Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.

JBS -resources, investigation, data curation, formal analysis, writing-original draft.

MM-resources, investigation, writing-review and editing.

EH-investigation, writing-review and editing.

SF-investigation, writing-review and editing.

JD-investigation, writing-review and editing.

SP-investigation, writing-review and editing.

EHH-investigation, writing-review and editing.

PP-investigation, data curation writing-review and editing.

JB-investigation, data curation writing-review and editing.

LT-investigation, data curation writing-review and editing.

WS- data curation writing-review and editing

MR-data curation writing-review and editing.

DS-data curation writing-review and editing.

MET-conceptualisation, investigation, data curation writing-review and editing

DE-investigation, writing-review and editing.

VW-formal analysis, investigation, data curation writing-review and editing.

MDC-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.

NB-Conceptualisation, resources, investigation, writing-review and editing, project administration, supervision. JH-Conceptualisation, resources, investigation, writing-review and editing.

GD-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.

ACM-Conceptualisation, methodology, resources, investigation, writing-original draft, project administration, formal analysis, funding acquisition, supervision.

The study was funded by Addenbrooke's Charitable Trust and the NIHR Cambridge Biomedical Resource Centre (grant held by Professor Dougan). Dr Török is supported by a Clinician Scientist Fellowship (funded by the Academy of Medical Sciences and the Health Foundation) and by the NIHR Biomedical Research Centre. Dr Conway Morris is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z). The metagenomic sequencing was funded by the Wellcome Trust.

Declaration of interest: MDC is the inventor on a patent held by the Secretary of State for Health (UK Government) EP2788503, which covers some of the genetic sequences used in this study. All other authors declare no conflict of interest.

Ethical permissions: The study was approved by the Leeds East Research Ethics Committee (17/YH/0286) and registered with clinicaltrials.gov (NCT03996330). The retrospective assessment of routinely collected data from the comparator group received a consent waiver and was conducted under a protocol approved by the institutional review board (A095506). Informed consent was obtained from the patient or a proxy decision maker where the patient lacked capacity, follow-up consent was sought when patient recovered capacity.

Introduction For many decades the diagnosis of infectious diseases has relied on a combination of clinical assessment and the culture of microorganisms. However, it is common for patients with clear clinical evidence of infection to have negative microbiological cultures. 1,2 Furthermore, the time taken to obtain a result by conventional culture can be several days.³ Optimising antimicrobial therapy can be challenging, especially in patients who are at risk of multidrug resistant organisms.² In critically ill patients, this frequently results in the empiric use of several broad-spectrum agents, with predictable consequences for antimicrobial resistance and other forms of antimicrobial-related harm. 4 Conversely, failure to identify the causative organism can lead to failure to select the correct antimicrobial, which is associated with poor outcomes.⁵ Pneumonia amongst ventilated, critically ill patients can be especially difficult to diagnose.⁶ Most critically ill patients are systemically inflamed. clinical examination is unreliable and there are multiple causes of radiographic lung infiltrates most of which are non-infectious. In the case of ventilator-associated pneumonia (VAP) it is estimated that only 20-40% of patients suspected of having infection actually have it confirmed, ¹⁰ although this confirmation relies on the imperfect diagnostic standard of microbiological culture. The development of host-based biomarkers for infection, such as C-reactive protein, 11 procalcitonin, 12 and alveolar cytokine concentrations¹³ have been advanced as useful measures to help rationalise antimicrobial use. However, their utility in the diagnosis 11,12 and antimicrobial stewardship 14,15 of pneumonia has been challenged. There is, therefore, a pressing need for rapid, sensitive, multi-pathogen focussed diagnostic tests for pneumonia which can aid effective and efficient antimicrobial optimisation. The use of TaqMan array cards (TAC), enabling single-plex real-time polymerase chain reaction (RT-PCR) to simultaneously target multiple respiratory pathogens, has previously shown promising results compared to conventional culture methods. ¹⁶ However, previous experience had demonstrated that multiplex PCR with restricted coverage of common respiratory pathogens had a limited impact on clinical decision making. ¹⁷ In this study we set out to evaluate the clinical utility of a customised TAC based syndromic diagnostic for severe pneumonia.

1

2

4

5 6

7

8

9

10

11 12

13

14 15

16

17

18 19

202122

23

24

25

26

27

28

Methods Detailed methods are included in the Supplementary appendix. Setting Patients were recruited from a single, 20 bedded teaching hospital Intensive Care Unit (ICU). The unit is a mixed general medical-surgical unit which supports solid organ and stem-cell transplantation and haematologyoncology services. Recruitment Prospectively identified patients were eligible for inclusion if they were receiving invasive mechanical ventilation, the treating clinician suspected pneumonia and was planning to perform diagnostic bronchoscopy. Consent was obtained from the patient or a proxy decision maker. Patients who were not included in the study due to lack of study team availability, and those from the month prior and month following the study, had their data reviewed retrospectively and acted as a comparator group. **Test development** Organism coverage for the TAC was selected from the known microbial flora encountered in the ICU, supplemented by the literature concerning causative organisms reported in severe pneumonia^{1,2,6,1017,18} The species covered by the card are shown in figure 1. The card also included primers to target the endogenous control RNase P and the internal control MS2. All primers were validated prior to clinical use and tested against Public Health England's quality control for molecular diagnostics pilot external quality assessment (QCMD EQA) samples (supplemental section). Sampling procedure Bronchoscopy was undertaken in accordance with existing unit protocols and similar to that used in previous studies. 10 An ethylenediaminetetraacetic acid (EDTA) blood sample and blood culture (BACTEC, Beckton Dickinson, Winnersh, UK) were taken at the time of bronchoscopy. Conventional microbiological testing Bronchoalveolar lavage (BAL) samples were processed according to the UK Standards for Microbiology Investigations (SMI).¹⁹ Further details of conventional culture and in-house multi-plex PCR assays are contained in the supplemental section. Following review by a consultant clinical scientist, results were returned to the ICU team. Clinical microbiology advice was available 24 hours/day, and patients underwent weekday daily combined ICU-Microbiology multidisciplinary review in keeping with existing unit practice (weekend microbiology input was only on specific request). The study did not mandate any course of action by the treating clinical team, however the notes were retrospectively reviewed by a member of the study team, not involved in the clinical decision making process, to assess whether the information from the TAC had influenced patient management. Conventional microbiology

32

33 34

35 36

37

38

39

40 41

42

43

44

45

46

47 48

49

50 51

52

53

54

55 56

57

58

59

60 61

62

63 64

65 66

67

68

69

70

results were returned to clinicians via the electronic health record; however in practice these were returned sometime after the TAC results. Data were collected on the use of antibiotics amongst patients in the study and the comparator group, with the number of days alive and free of antibiotics in the seven days following lavage compared (antibiotic-free days, AFDs) for first episode only. Seven days was selected as being in keeping with a recent RCT of a novel diagnostic in ventilated pneumonia¹⁵ and was judged to be a timeframe in which the specific impact of the TAC might be seen.

TAC validation

The TAC was compared to the reference standard of conventional bacterial culture and PCR, in combination with metagenomic sequencing, as it is recognised that culture alone is an imperfect measure of the microbial composition of a sample. As lavage samples are low microbial biomass samples generally dominated by human DNA, a combination of shotgun and 16S amplicon sequencing approaches were used. Details of the conventional microbiology and metagenomic sequencing are in the supplemental methods.

Economic analysis

A flow model for establishing diagnostic tests and decision points for antibiotic prescribing was created (figure E1). Costs for conventional microbiological tests were obtained from the Public Health England Clinical Microbiology and Public Health Laboratory, whilst costs for the TAC were determined by the cost of the array consumables and estimated staff time to run the assay.

Statistical analysis

The protocol, agreed prior to study initiation, set out the primary and secondary endpoints. The co-primary endpoints were agreement between conventional microbiology, with sequencing added to form a composite reference during the study, and the TAC, assessed by sensitivity and median time to result for conventional culture and TAC assessed by Wilcoxon matched-pairs test. Where a reference standard was missing this was treated as 'negative', in accordance with pessimistic assumptions about index test performance (i.e. if reference standard was missing any TAC results were assumed to be 'false positive' for determination of specificity). Indeterminate results were excluded from analysis. Analysis was conducted using Graphpad prism v5.0 (Graphpad inc, San Diego, CA).

Study size

As the incidence of infections with specific organisms could only be inferred from conventional culture which is known to be insensitive, a formal power calculation was not performed. A pragmatic study size of 100 patients was selected to balance cost against including sufficient numbers to be able to make a judgement on card utility.

Ethical and regulatory approvals and funding

The study was approved by the Leeds East Research Ethics Committee (17/YH/0286) and registered with clinicaltrials.gov (NCT03996330). The retrospective assessment of routinely collected data from the comparator group received a consent waiver and was conducted under a protocol approved by the institutional review board (A095506).

Results Recruitment Following technical validation of the TAC (supplemental section, table E1) 100 patients were recruited between February 2018 and August 2019. The study flow diagram is shown in figure 2. 64% of eligible patients were recruited, with lack of the study team availability the only reason for non-recruitment. Table 1 shows demographic and clinical features of the study population and comparator group. Although inclusion criteria were pragmatic and only required clinician suspicion of pneumonia, in practice all patients met ECDC criteria for clinical pneumonia²⁰. Five patients were recruited twice, having suffered a subsequent respiratory deterioration following the initial episode. These episodes occurred a median of 11 days apart (range 4-42 days). In one further patient samples were taken from two separate segments of the lung during the same bronchoscopic procedure. As these were taken at the same time only the primary sample corresponding to the site of maximal radiographic change has been included in the main results. The results of both samples are presented in table E2 for completeness. Although transitory reduction in oxygenation was common during bronchoscopy, no patient in the study suffered any protocol-defined serious adverse events. Time to result The co-primary outcome for this study was time to result for the microarray compared to validated conventional microbial culture. Median difference in time to result between TAC and conventional culture was 61 hours (range 19-256) (figure E2). The minimum TAC time to return was 4 hours, with median time to result 22 hours (range 4-42), most of the delays in results arose from not running the card outside routine working hours. Comparison of organisms detected by TAC compared to conventional microbiology and sequencing. 179 organisms were identified from 100 patients on the TAC (table 2 and E3), excluding duplicate organisms (organisms detected at genus and species level or species and sub-type level). Conventional microbial culture and PCR detected 66 organisms (table 2 and E3) whilst sequencing revealed 109 organisms from 98 patients (two patients could not be sequenced), combined a total of 118 organisms were detected. Ten organisms detected by conventional microbiology or sequencing were missed by the TAC (overall sensitivity 92%, 95% CI 85-96%). 71 organisms were detected by TAC only, considering all targets, 4952 tests were negative by TAC, giving a specificity of 99% (95% CI 98-99%). TAC cards which were negative for all pathogens in 21 cases. with 18 of these fully negative on both conventional microbiology and sequencing. Out of the 82 samples with pathogens detected, only 31 presented with a single organism. In the majority of cases (51 samples), we observed mixed infections (table E3 and figure E3). In terms of the 10 'missed organisms', one organism, that was positive by both culture and sequencing albeit in different patients, was Citrobacter freundii, for which we did not have a sequence on the card. A further five pathogens were detected by sequencing (Staphylococcus aureus, Legionella spp., and Staphylococcus epidermidis) or both culture and sequencing (two E. faecium), and although detected by TAC, these did not pass the internal quality control standards required for reporting and were considered 'negative' results. The

113

114

115

116

117

118

119

120

121122

123

124

125

126

127

128

129 130

131

132

133

134

135 136

137

138

139

140

141

142

143

144

145

146

147 148

149

150

151

remaining three organisms, two Rhinovirus by conventional PCR and one Staphylococcus spp. by sequencing, were not detected by TAC at all. In one case the conventional culture was reported as 'Mixed respiratory tract flora at >10⁴ CFU/ml' with TAC detection of E. faecium, C. albicans, and S. epidermidis which was deemed an indeterminate result for conventional culture, however sequencing was successful on this sample. One case of Aspergillus fumigatus was detected on the TAC, and although no fungal organisms were grown on culture the lavage galactomannan antibody test was highly positive (5.92 Units, reference range <0.5units), the patient had radiographic evidence of fungal pneumonia and multiple risk factors for invasive aspergillosis. Notably, in the 10 samples from the 5 patients enrolled twice, the organisms detected demonstrated homogeneity between samples taken within the same ICU admission (table E2), as did samples taken from two separate areas of the lung on the same day. **Quantitation** In total, 25 organisms were grown on conventional culture at $\geq 10^4$ CFU/ml, the conventional cut off for quantitative culture of lavage.²⁰ The median cycles to threshold (Ct) for these organisms that were also detected by TAC was 27 (IOR 24-29, range 20-33), by contrast culturable organisms detected on TAC but not on culture had a median Ct of 32 (IOR 30-34, range 22-38). A similar range of Ct values was noted in the OCMD EOA pilot study samples (table E1). Comparison of conventional blood culture and TAC Nuclear material extracted from the EDTA blood sample was run on the array card. This was compared with blood culture taken at the time of bronchoscopy. The yield from both conventional culture and TAC was limited, with 5 positive organisms on conventional testing and 20 organisms detected on the array card (table E4). Streptococcus pneumoniae was the only bacteria detected from blood on the array, being detected 5 times. 14 of the organisms were detected in both lavage and blood, including all the cases of Streptococcus pneumoniae in blood. Impact on clinical decision making In 53 (53%) of patients the results from the TAC led to a change in clinical management (table 3). 64% of decisions were decreases in antimicrobial intensity. The most common de-escalation decisions were stopping macrolides in the absence of atypical organisms and de-escalating from anti-pseudomonal penicillins and carbapenems to narrower spectrum beta-lactam antibiotics (table E5). 27% of decisions involved broadening of the spectrum of coverage and in six cases the result prompted a search for an alternative diagnosis (three also involved de-escalation of antimicrobials). In some patients several changes occurred. In a further five cases the research team's opinion was that management could have been changed (all five cases would have been deescalation). Patients in the comparator group demonstrated significantly fewer antibiotic-free days (distribution of AFDs shown in figure 3).

153

154

155

156

157 158

159

160

161162

163

164

165 166

167

168 169

170

171

172173

174

175

176

177

178

179

180 181

182

183

184

185

186

187

188

189

190

Economic analysis The costs of conventional microbiological testing were £222 (US\$ 286), whilst the costs of TAC and bacteriological culture for sensitivity testing was £171 (US\$ 220), a difference of £51 (US\$65). Figure E1 shows workflow with and without TAC. **Discussion** We demonstrate that a customised molecular diagnostic, designed to meet the needs of a specific clinical setting produced accurate results in a clinically important timeframe and influenced patient management decisions. This was within the context of a well-established antimicrobial stewardship programme. Results were returned to clinicians 61 hours faster than conventional cultures, and the accuracy of the results was confirmed by culture, sequencing or both. Notably, many previous studies in respiratory infection specifically exclude critically ill patients, who are those who may suffer the most from inappropriate antimicrobial therapy⁵ but are also at greatest risk of antimicrobial-associated harm. 4 Importantly this can be achieved at no additional cost to the laboratory. Molecular diagnostic platforms for respiratory infection syndromes have, until recently, largely focussed on viral pathogens. However, the need to optimise antimicrobial therapy whilst limiting the over-use of these precious drugs has led to repeated calls for effective bacterial-focussed diagnostics. ²¹ TACs have been previously reported for use in pneumonia. 17,22,23 However, apart from our previous report 17 that demonstrated limited clinical impact due to restricted organism coverage, none of the other reports have included ventilated patients and all were restricted to retrospective analysis of stored samples. Commercial multiple-pathogen arrays that include respiratory bacteria have recently become available. However, reports of their use in ventilated patients also remain restricted to retrospective analysis of stored samples. ^{3,24,25} These commercially available assays lack the breadth of coverage and the customisability of the TAC, with one evaluation noting that clinical use of the assay investigated to withhold antibiotics could have led to inappropriate undertreatment.³ Patients who develop critical illness as a result of pneumonia present a particular diagnostic challenge, as these infections may involve a variety of bacterial, fungal and viral pathogens.² Although the source of acquisition of severe pneumonia may indicate the risk of particular organisms, ^{6,26,27} this is an imperfect method of predicting the causative organism.²⁸ The difficulty in predicting the causative organism, coupled with the insensitivity of culture-based culture detection leads to frequent use of multiple, broad-spectrum antimicrobials. Even when culture results in growth of an organism, the time-frame on which these results are available compromises effective antimicrobial stewardship, and in practice de-escalation is rare²⁹ as there remains a constant concern about organisms which remain undetected. Although there is now widespread acceptance of the presence of a respiratory microbiome, ^{30,31} the lungs of ventilated patients present a challenge to highly sensitive molecular diagnostics. The proximal respiratory tract of ventilated patients becomes rapidly colonised with predominantly Gram negative organisms³² as the

193

194

195

196

197 198 199

200201

202

203

204

205

206

207

208

209 210

211

212

213214

215

216

217218

219

220221

222

223224

225

226

227228

229

230231

microbiome is disrupted. 31,33 This can occur in the absence of infection, and there is a risk that highly sensitive techniques will be more susceptible to the detection of colonising organisms, driving an unintended increase in antimicrobial use. The use of semi-quantitative cultures of protected lower airway specimens, with growth above 10⁴ colony forming units/ml for BAL have been used to distinguish infection from colonisation. 20,34 We adapted this approach in this study, using the quasi-quantitative Ct value provided by RT-PCR and testing protected broncho-alveolar samples. This ensured that the dominant change in practice seen was the deescalation of antimicrobials. However, we also found a substantial proportion of changes involved broadening the coverage to cover organisms that had not been anticipated. Had our study been judged by conventional 'reduction in antimicrobial use' the modest reduction in antibiotic-free days seen may have been considered irrelevant. We suggest that consensus measures of antimicrobial optimization be developed to assess the clinical utility of novel microbial diagnostics.

One of the problems that has beset microbial diagnostics studies has been the absence of a 'gold standard' against which the candidate can be assessed, ³⁵ as it is acknowledged that conventional culture is imperfect. For this study we used a combination of conventional culture and metagenomic sequencing. All but 10 organisms identified by conventional microbiology or sequencing were detected by the TAC. The card was, overall, more sensitive than either of the confirmatory techniques. We do not believe these additional TAC hits to be true 'false positives' but rather reflect the enhanced sensitivity of targeted PCR. Notably, all of these TAC-only detections occurred at high Ct values, indicating limited and almost certainly clinically irrelevant numbers of organisms. We therefore believe that the sequencing and culture results can give clinicians considerable confidence in the results provided.

The selection of organisms targeted on the card was crucial, and informed by our previous experience where omission of key organisms of concern significantly limited the impact of a similar card. ¹⁷ Given the case mix of our unit, with a high proportion of immunosuppressed patients, we opted to include a number of low pathogenicity organisms, such a coagulase-negative *staphylococci*, *enterococci* and *Candida albicans* on the card. The detection of these organisms can be challenging to interpret, and indeed given the knowledge that many critically ill patients may be immunoparietic even if not classically immunosuppressed their significance remains uncertain. Their presence, and the frequency of polymicrobial detection, indicates a dysbiotic response in the lungs of critically ill patients, ^{31,33,34,36} and knowing how to respond to this dysbiosis remains an area of uncertainty. One of the advantages of the TAC as a platform is its customizability, and single targets can be easily added or modified without having to re-optimise the entire panel, that allowed us to deploy the card during the recent COVID19 pandemic³⁷, and will also allow it to be adapted to other units or geographic locations. Narrowing of spectrum was based on expert microbiological advice in light of the known prevalence of antimicrobial resistance in species identified in our area, the addition of further AMR genes to the TAC may help further narrow spectra.

This study had a number of strengths. We developed a test that met the needs of a particular intensive care unit, and implemented it in the context of a well-established stewardship programme. We managed to include a significant proportion of the patients undergoing bronchoscopic investigation for pneumonia, and thus our

results are likely to be representative of our unit's workload. However, validation in external cohorts is required to demonstrate generalisability. A potential weakness is that as an observational study, the assessment of impact on clinical decision making is susceptible to bias, and we cannot be certain that the changes to clinical management made would not have occurred without the TAC result. However, the more objective increase in AFDs relative to the comparator group is supportive of genuine impact. Our comparator group was similar to the study group in terms of demographic and illness severity indices, and by being drawn from the same time period of the study being managed by the same clinicians, in an environment in which a study which may influence antimicrobial stewardship was occurring, therefore we believe the differences seen are indeed due to the diagnostic approach used. However, we cannot exclude the possibility that a comparator group made up of patients admitted at times when the study team were not available may differ in unmeasured ways from the study cohort. The similar 28-day mortality suggests that our TAC-based approach, with overall reduction in antibiotic intensity, was not harmful. Although one patient was positive by TAC for Aspergillus, with raised galactomannan and supportive radiology, two further patients met similar criteria for probable invasive aspergillosis but were negative for Aspergillus by TAC. Whilst these counted as 'true negatives' as we had set out in our original protocol, we suggest caution in the use of this card for ruling out Aspergillus infection. As there are no agreed standards for sequencing to determin the presence of pathogens in clinical samples, we relied on pragmatic criteria agreed within the research team. However, given the acknowledged insensitivity of conventional culture³⁵, we believe this adds significant additional confirmation of the performance of the TAC.

In conclusion, we have developed a customised respiratory diagnostic which covers a broad range of pathogenic organisms, and validated it against the standard of conventional microbiology as well as metagenomic sequencing. In a pragmatic, observational study of the implementation of this tool, within the context of an established antimicrobial stewardship program, we were able to see significant impact on clinical decision making. Although external validation is required, we believe this represents a promising new approach to the management of severe pneumonia with the potential to impact on patient management and outcomes.

Acknowledgements

The authors thank the consultant intensivists of the John V Farman Intensive Care Unit, Drs P Bradley, P Featherstone, S Ford, M Georgieva, A Johnston, R Mahroof, J Martin, J Preller, K Patel, C Summers M Trivedi, J Varley, Pharmacist L Radford and the nursing and physiotherapy teams who managed the patients, and the patients and their families who consented to the study. We also thank Torsten Seemann for access to his Kraken database.

References:

- 1. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. *Thorax*. 2011;66(4):340-346.
- 2. Vincent J-L, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *JAMA*. 2020;323(15):1478–10.
- 3. Gadsby NJ, McHugh MP, Forbes C, et al. Comparison of Unyvero P55 Pneumonia Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting. *Eur J Clin Microbiol Infect Dis*.
- 327 $2019;38(6):1171 \square 1178.$
- 4. Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Morris AC. Antimicrobial-associated harm in critical care: a narrative review. *Intensive Care Med.* January 2020:1-11.
- Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical Importance of Delays in the
 Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia. 2002;122(1):262-268.
- Morris AC. Management of pneumonia in intensive care. *J Emerg Crit Care Med.* 2018;2(0):101-101.
- 7. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The Natural History of the Systemic Inflammatory Response Syndrome (SIRS). *JAMA*. 1995;273(2):117–5.
- 337 8. Lichtenstein D, Goldstein I, Mourgeon E, Cluzel P, Grenier P, Rouby J-J. Comparative 338 diagnostic performances of auscultation, chest radiography, and lung ultrasonography in acute 339 respiratory distress syndrome. *Anesthesiology*. 2004;100(1):9-15.
- 9. Meduri GU, Mauldin GL, Wunderink RG, et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. *Chest.* 1994;106(1):221-235.
- 10. Conway Morris A, Kefala K, Wilkinson TS, et al. Diagnostic importance of pulmonary interleukin-1 {beta} and interleukin-8 in ventilator-associated pneumonia. *Thorax*. 2010;65(3):201-207.
- 11. Povoa P, Coelho L, Almeida E, et al. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. *Eur Resp J.* 2005;25(5):804-812.
- Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia
 in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic
 review and individual patient data meta-analysis. *Critical Care*. 2014;18(2):1-11.
- Hellyer TP, Morris AC, Mcauley DF, et al. Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumonia. *Thorax*. 2015;70(1):41-47.
- Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower
 Respiratory Tract Infection. N Engl J Med. 2018;379(3):236-249.
- 15. Hellyer TP, McAuley DF, Walsh TS, et al. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. *Lancet Resp Med.* December 2019:1-10.
- 356
 16. Steensels D, Reynders M, Descheemaeker P, et al. Clinical evaluation of a multi-parameter customized respiratory TaqMan® array card compared to conventional methods in immunocompromised patients. *J Clin Virol*. 2015;72:36-41.
- 359 17. Jones N, Conway Morris A, Curran MD et al. Evaluating the use of a 22-pathogen TaqMan array card for rapid diagnosis of respiratory pathogens in Intensive Care. *J Med Microbiol*. 2020; 69: 971-978.

- 18. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. *Clin Infect Dis.* 2016;62(7):817-823.
- 19. Public Health England. Investigation of bronchoalveolar lavage, sputum and associated specimens UK SMI B 57 issue 3.5 (May 2019) (available from
- https://www.gov.uk/government/publications/smi-b-57-investigation-of-bronchoalveolar-lavage-sputum-and-associated-specimens) accessed 20/5/2020
- 20. Plachouras D, Lepape A, Suetens C. ECDC definitions and methods for the surveillance of healthcare-associated infections in intensive care units. *Intensive Care Med.* October 2018:1-3.
- The Lancet Respiratory Medicine. Pneumonia research: time to fill in the gaps. *Lancet Resp*Med. 2019;7(12):993.
- Wolff BJ, Bramley AM, Thurman KA, et al. Improved Detection of Respiratory Pathogens by
 Use of High-Quality Sputum with TaqMan Array Card Technology. Onderdonk AB, ed. *J Clin Microbiol.* 2017;55(1):110-121.
- Hercik C, Cosmas L, Mogeni OD, et al. A diagnostic and epidemiologic investigation of acute febrile illness (AFI) in Kilombero, Tanzania. Schildgen O, ed. *PLoS ONE*. 2017;12(12):e0189712-e0189720.
- 24 Pulido MR, Moreno-Martínez P, González-Galán V, et al. Application of BioFire FilmArray
 379 Blood Culture Identification panel for rapid identification of the causative agents of ventilator-associated
 380 pneumonia. *Clini Micro Infect*. 2018;24(11):1213.e1-1213.e4.
- 381 25 Yoo IY, Huh K, Shim HJ, et al. Evaluation of the BioFire FilmArray Pneumonia Panel for rapid detection of respiratory bacterial pathogens and antibiotic resistance genes in sputum and endotracheal aspirate specimens. *Int J Infect Dis.* 2020;95:326-331.
- American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med.* 2005;171(4):388-416.
- Chastre J, Fagon J-Y. Ventilator-associated pneumonia. *Am J Respir Crit Care Med.* 2002;165(7):867-903.
- 389 28. Yap V, Datta D, Metersky ML. Is the Present Definition of Health Care—Associated 390 Pneumonia the Best Way to Define Risk of Infection with Antibiotic-Resistant Pathogens? *Infect Dis* 391 *Clin North Am.* 2013;27(1):1-18.
- 392 29. Kollef MH, Morrow LE, Niederman MS, et al. Clinical Characteristics and Treatment Patterns 393 Among Patients With Ventilator-Associated Pneumonia. *Chest.* 2006;129(5):1210-1218.
- 39. Langelier C, Kalantar KL, Moazed F, et al. Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults. *Proc Natl Acad Sci USA*. 2018;319:201809700.
- 397 31. Zakharkina T, Martin-Loeches I, Matamoros S, et al. The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. *Thorax*. 2017;72(9):803-810.
- 400 32. Ewig S, Torres A, El-Ebiary M, et al. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. *Am J Respir Crit Care Med.* 1999;159(1):188-198.
- 403 33. Roquilly A, Torres A, Villadangos JA, et al. Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia. *Lancet Resp Med.* 2019;7(8):710-720.

405 34. Morris AC, Kefala K, Simpson AJ, et al. Evaluation of the effect of diagnostic methodology 406 on the reported incidence of ventilator-associated pneumonia. Thorax. 2009;64(6):516-522. 407 doi:10.1136/thx.2008.110239. 408 Bhat N, O'Brien KL, Karron RA, Driscoll AJ, Murdoch DR, the Pneumonia Methods Working 35. 409 Group. Use and Evaluation of Molecular Diagnostics for Pneumonia Etiology Studies. Clin Infect Dis. 410 2012;54(suppl 2):S153-S158. 411 36. Nolan TJ, Gadsby NJ, Hellyer TP, et al. Low-pathogenicity Mycoplasma spp. alter human 412 monocyte and macrophage function and are highly prevalent among patients with ventilator-acquired 413 pneumonia. Thorax. 2016;71(7):594-600. 414

Parameter Study patients Comparator group (95 patients) (71 patients) Median age (range) 60 (21-86) 62 (18-83) n (%) female 41 (43 %) 27 (38 %) Median (IQR) functional comorbidity 1(2)n (%) with community-acquired 34 (36%) 20 (28%) pneumonia n (%) hospital-acquired pneumonia 61 (64%) 51 (72%) 24 (39%) of HAP n (%) ventilator-associated 27 (52%) Median (IQR) APACHE II score on 16 (10) 16 (9) admission % receiving antibiotics at time of 82% 96% lavage Median (IQR) Fi02 prior to 0.5(0.25)0.5(0.30)

Table 1: clinical and demographic details of patients enrolled in the study. APACHE II, acute physiology and chronic health evaluation II, Fi02, fraction of inspired oxygen.

10.7 (9.5)

8.8 (8.63)

146 (154)

21 (30%)

10.5 (12.4)

8.6 (11.5)

198 (153)

30 (32%)

415

bronchoscopy

concentration 28 day Mortality

416 417 418

419

420 421 Median (IQR) white cell count

Median (IQR) neutrophil count

Median (IQR) C-reactive protein

Organism detected	Frequency (by conventional microbiology)	Frequency (by TAC)	Frequency (by sequencing)
Bacteria	30		
Citrobacter freundii	1***	0	1***
Enterobacter cloacae	2	8	3
Enterococcus faecalis	0	3	0
Enterococcus faecium	3	7	7
Escherichia coli	6	14	6
Klebsiella pneumoniae	3	5	3
Enterobacteriaceae	0	1	2
(not further specified)			
Haemophilus influenzae	0	3	2
Legionella pneumophilia	1*	1	1
Legionella spp. (non-pneumophilia)	0	2	2
Morexella catharralis	0	1	0
Mycoplasma pneumoniae	0	1	1
Proteus spp.	0	2	0
Pseudomonas aeruginosa	2	5	4
Serratia marcescens	1	3	0
Staphylococcus aureus	2	8	8
Staphylococcus epidermidis	0	9	2
Other coagulase negative Staphylococcus	0	1	2
Other Staphylococcus spp. (not further specified)	0	0	1
Stenotrophomonas maltophilia	2	4	2
Streptococcus pneumoniae		9	6
Streptococcus pyogenes	0	1	0
Streptococcus spp. (not further specified)	0	23	10
Mixed upper respiratory tract flora	1	N/A	N/A
Fungi	<u>*</u>	1,711	1111
Aspergillus spp.	0**	1	0
Candida albicans	1	12	10
Candida spp.	0	1	1
Pneumocystis jirovecii	4	4	3
Viruses			-
Coronavirus#	0	3	1
Cytomegalovirus	5	7	4
Epstein-Barr Virus	1	6	1
Herpes simplex virus	7	11	7
Human metapneumovirus	1	1	1
Influenza A	7	7	5
Influenza B	3	3	2
Parainfluenza virus	4	4	4
Rhinovirus	8	8	7

Table 2: Organisms detected by conventional microbiological testing (left hand column), by TAC (middle column), and by microbial sequencing (right hand column). * Legionella urinary antigen test positive. ** Positive BAL galactomannan enzyme immunoassay (>0.5 units) with CT consistent with fungal pneumonia and known risk factors but fungal cultures were not positive. ***One hit not found in same patient. # -refers to human coronavirade OC43 and NL63, no tests were undertaken for SARS-CoV2 and final testing occurred in August 2019.

Type of change		
Reduction in spectrum	Stopping therapeutic antimicrobial agent(s)*	33
	Changing to a narrower spectrum	7
	Withholding planned treatment	2
Increase in spectrum	Addition of further antimicrobials	14
	Change to broader spectrum agent	4
Alternative diagnosis investigated or	Computed Tomography scan	2
made	Tissue biopsy	2
	Alternative diagnosis made	2

 $Table \ 3: changes \ in \ treatment \ made \ as \ a \ result \ of \ findings \ from \ the \ TAC \ (some \ patients \ had \ more \ than one \ change \ within \ a \ given \ type - e.g. \ both \ reduction \ spectrum \ and \ cessation \ of \ antimicrobials) \ .$

^{*}in two cases antimicrobials were reduced to prophylactic dose as patients remained at risk of opportunistic infections




Figure 1: layout of TAC




Figure 2: recruitment flow chart




Figure 3: Distribution of days alive and free of antibiotics in the seven days following bronchoscopy and lavage in the TAC and comparator cohorts. Following first lavage only for patients who had more than one BAL during ICU admission. Numbers in each category and percentage shown below graph, p value by Mann-Whitney U test.

